Mark Bondin

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis

David Back, Pamela S. Belperio, Mark Bondin et al. · Journal of Viral Hepatitis · 2019 · 27 citations · Full text

Medicine, Pharmacology, Psychiatry +17

Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir

Alessio Aghemo, Yves Horsmans, Stefan Bourgeois et al. · Infectious Diseases and Therapy · 2021 · 21 citations · Full text

Pharmacy, Pharmacotherapy, Clinical Pharmacology +16

Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C‐Registry

Hartwig Klinker, Uwe Naumann, Martin Rössle et al. · Liver International · 2021 · 15 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Real‐world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1‐ and 4‐infected patients with diverse comorbidities and comedications: A pooled analysis of post‐marketing observational studies from 13 countries

Péter Ferenci, Stefan Bourgeois, Peter Buggisch et al. · Journal of Viral Hepatitis · 2019 · 14 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Long‐term safety and efficacy results in hepatitis C virus genotype 1‒infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ‐I and TOPAZ‐II trials

Fred Poordad, RuiSarmento E. Castro, Armen Asatryan et al. · Journal of Viral Hepatitis · 2020 · 14 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17